Safety and Tolerability of the Nutritional Supplement, Nicotinamide Riboside, in Systolic Heart Failure
营养补充剂烟酰胺核苷治疗收缩性心力衰竭的安全性和耐受性
基本信息
- 批准号:9113264
- 负责人:
- 金额:$ 11.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-01 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:ATP Synthesis PathwayActivities of Daily LivingAffectAnimal ModelBioavailableBiologyBloodCardiacCaringChronicChronic stressClinic VisitsDataDevelopmentDiet and NutritionDietary SupplementationDiseaseDoseEchocardiographyElectrolytesEnsureEtiologyExploratory/Developmental GrantFlushingGlucoseGoalsHealthHeartHeart failureHumanImageImpairmentInnovative TherapyInsulinInsulin ResistanceInterventionLaboratory FindingLeft Ventricular Ejection FractionLeukocytesLinkLipidsMaximum Tolerated DoseMedicalMitochondriaMitochondrial ProteinsModelingMonitorMusMuscleMyocardialMyocardial dysfunctionNADHNIH Program AnnouncementsNMR SpectroscopyNiacinamideNicotinamide MononucleotideNicotinic AcidsOralOxidative PhosphorylationOxidative StressParticipantPatientsPilot ProjectsPlacebosPreventionProductionProtein AcetylationPruritusRandomizedRelative (related person)Research Project GrantsRodent ModelSafetySerumStarvationSupplementationSurrogate EndpointSymptomsSystolic heart failureTestingTherapeutic UsesThree-Dimensional EchocardiographyTimeTissuesTranslatingUric AcidVentricular FunctionVisitWalkingWitbasedietary supplementsimprovedinnovationmitochondrial dysfunctionmouse modelnew therapeutic targetnicotinamide-beta-ribosideperipheral bloodpressurepreventresponsescreeningtherapy development
项目摘要
DESCRIPTION (provided by applicant): Medical care of heart failure (HF) has been stagnant for the past 20 years; innovative therapy is urgently needed. A novel therapeutic target, mitochondrial dysfunction, has been implicated in multiple diseases, including heart failure. However, there currently is no specific treatment for mitochondrial dysfunction in human heart failure or any other disease. Mitochondria-based therapy development has been hampered both by limited understanding of how mitochondrial impairment causes cardiac dysfunction, and by a lack of interventions shown to improve mitochondrial function. Recently, we demonstrated in a murine model, that impaired mitochondrial oxidative phosphorylation led to an increased myocardial NADH/NAD+ ratio and increased mitochondrial protein acetylation, without affecting mitochondrial ROS production or ATP synthesis. These changes rendered the heart susceptible to chronic stresses, which accelerated the development of heart failure. We observed a similar increase of NADH/NAD+ ratio and increase in protein acetylation in animal models of heart failure due to chronic pressure overload with no prior mitochondrial dysfunction. Supplying the NAD+ precursor, nicotinamide mononucleotide (NMN), to these mice normalized the NADH/NAD+ ratio, prevented increased mitochondrial protein acetylation and improved cardiac function. Though NMN is not orally bioavailable, we and others have shown that oral supplementation with nicotinamide riboside (NR), the precursor from which NMN is produced, also decreases (normalizes) tissue NADH/NAD+ ratio and improves mitochondrial function in mouse models. These animal model results suggest a conceptually innovative mechanism linking mitochondrial dysfunction to the development and progression of heart failure that is distinct from the existing hypotheses of oxidative stress and energy starvation. Thus, we hypothesize that oral supplementation with NR will improve the NADH/NAD+ ratio caused by mitochondrial dysfunction during chronic stresses, and improve functional capacity and ventricular function in systolic heart failure. We therefore propose a first-in-human, safety and tolerability trial of the nutritional supplement, nicotinamide riboside (NR) in 30 participants wit clinically-stable, systolic heart failure. NR is a relative of niacin, but a closer relative of nicotinamide which, unlike niacin, does not induce flushing or pruritis and has no effect on lipid levels. NR does not induce insulin resistance or dysglycemia in mouse models. Thus, NR would potentially be cheap, safe, well-tolerated and readily available. The application is in response to
the program announcement of "Nutrition and Diet in the Causation, Prevention, and Management of Heart Failure" as NR has recently been approved for human use as a health supplement. As NR has not been used therapeutically in heart failure patients, we will utilize the R21 mechanism to support a pilot study with the following aims: 1) to determine the safety and tolerability of NR in patients with clinically-stable, systolic heart failure (LVEF <40%); 2) to determine whether, at the doses employed, NR has measureable effects on leukocyte NAD+ level and NADH/NAD+ ratio; and 3) to explore the potential range of effects of NR supplementation on heart failure surrogate endpoints.
描述(申请人提供):心力衰竭(HF)的医疗护理在过去的20年里一直停滞不前;迫切需要创新的治疗方法。线粒体功能障碍是一种新的治疗靶点,它与包括心力衰竭在内的多种疾病有关。然而,目前还没有针对人类心力衰竭或任何其他疾病的线粒体功能障碍的特效药。由于对线粒体损伤如何导致心脏功能障碍的了解有限,以及缺乏改善线粒体功能的干预措施,基于线粒体的治疗发展一直受到阻碍。最近,我们在一个小鼠模型中证明,线粒体氧化磷酸化受损导致心肌NADH/NAD+比值增加,线粒体蛋白乙酰化增加,而不影响线粒体ROS的产生或ATP的合成。这些变化使心脏容易受到慢性压力的影响,从而加速了心力衰竭的发展。我们观察到,在没有线粒体功能障碍的慢性压力超负荷所致的心力衰竭动物模型中,NADH/NAD+比率和蛋白乙酰化水平也有类似的增加。向这些小鼠提供NAD+前体烟酰胺单核苷酸(NMN)可使NADH/NAD+比值正常化,防止线粒体蛋白乙酰化增加,并改善心功能。虽然NMN没有口服生物利用度,但我们和其他人已经表明,口服补充NMN的前体烟酰胺核苷(NR)也可以降低(正常化)组织NADH/NAD+比率,并改善小鼠模型的线粒体功能。这些动物模型结果表明,一种概念上的创新机制将线粒体功能障碍与心力衰竭的发展和进展联系起来,这与现有的氧化应激和能量饥饿假说不同。因此,我们假设口服NR可以改善慢性应激时线粒体功能障碍引起的NADH/NAD+比值,并改善收缩期心衰患者的心功能和心功能。因此,我们建议对30名临床稳定的收缩性心力衰竭患者进行首次人体安全性和耐受性试验,试验对象为营养补充剂烟酰胺核苷(NR)。NR是烟酸的近亲,但也是烟酰胺的近亲,与烟酸不同,它不会引起潮红和瘙痒,也不会对血脂水平产生影响。NR不会在小鼠模型中引起胰岛素抵抗或血糖紊乱。因此,天然橡胶有可能是廉价、安全、耐受性好和容易获得的。该应用程序响应于
“心力衰竭的起因、预防和管理中的营养和饮食”作为NR的计划公告最近已被批准作为健康补充剂用于人类。由于NR尚未用于心力衰竭患者的治疗,我们将利用R21机制支持一项先导性研究,目的如下:1)确定NR在临床稳定的收缩性心力衰竭(LVEF<;40%)患者中的安全性和耐受性;2)确定在所使用的剂量下,NR是否对白细胞NAD+水平和NADH/NAD+比率有可测量的影响;以及3)探索补充NR对心力衰竭替代终点的潜在影响范围。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kevin D. O'Brien其他文献
16 Weeks of Diabetogenic Diet are Sufficient To Induce Cardiac Hypertrophy and Fibrosis in a Murine Model of Diet-Induced Insulin Resistance and Cardiomyopathy
- DOI:
10.1016/j.cardfail.2012.06.074 - 发表时间:
2012-08-01 - 期刊:
- 影响因子:
- 作者:
Antonio Sta Teresa;Jinkyu Kim;Tomasz Wietecha;Kelly Hudkins;Charles E. Alpers;Kevin D. O'Brien - 通讯作者:
Kevin D. O'Brien
Patient-carried card prompts vs computer-generated prompts to remind private practice physicians to perform health maintenance measures.
患者携带的卡片提示与计算机生成的提示,提醒私人执业医生执行健康维护措施。
- DOI:
10.1001/archinte.1994.00420170105010 - 发表时间:
1994 - 期刊:
- 影响因子:0
- 作者:
Robert C. Turner;J. G. Peden;Kevin D. O'Brien - 通讯作者:
Kevin D. O'Brien
DIVERGENT EFFECTS OF VASODILATORS ON CARDIAC HYPERTROPHY AND INFLAMMATION IN A MURINE MODEL OF DIABETIC CARDIOMYOPATHY
- DOI:
10.1016/s0735-1097(11)60193-9 - 发表时间:
2011-04-05 - 期刊:
- 影响因子:
- 作者:
Kevin D. O'Brien;Warangkana Pichaiwong;Jinkyu Kim;Antonio Haw;Bardia Askari;Tomasz Wietecha;Kelly Hudkins-Loya;Charles E. Alpers - 通讯作者:
Charles E. Alpers
222: Lipoproteins in the Prediction of Coronary Artery Calcium (CAC) as Modified by Age in the Multi-Ethnic Study of Atherosclerosis (MESA)
- DOI:
10.1016/j.jacl.2008.04.039 - 发表时间:
2008-06-01 - 期刊:
- 影响因子:
- 作者:
Pathmaja Paramsothy;Gregory L. Burke;Ronit Katz;Kevin D. O'Brien;David S. Owens;Jeffrey L. Probstfield - 通讯作者:
Jeffrey L. Probstfield
Metformin, but not Diet-Induced Weight Loss, Decreases Myocardial Fibrosis in a Murine Model of Diet-Induced Insulin Resistance and Cardiomyopathy
- DOI:
10.1016/j.cardfail.2012.06.021 - 发表时间:
2012-08-01 - 期刊:
- 影响因子:
- 作者:
Tomasz Wietecha;Jinkyu Kim;Antonio Sta Teresa;Kelly Hudkins;Charles E. Alpers;Kevin D. O'Brien - 通讯作者:
Kevin D. O'Brien
Kevin D. O'Brien的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kevin D. O'Brien', 18)}}的其他基金
Mechanistic Studies of NAD+/NADH in Human Heart Failure
NAD/NADH 在人类心力衰竭中的作用机制研究
- 批准号:
10242151 - 财政年份:2019
- 资助金额:
$ 11.59万 - 项目类别:
Energy metabolism and NAD+/NADH in Right Ventricular Failure
右心室衰竭中的能量代谢和 NAD /NADH
- 批准号:
10629552 - 财政年份:2019
- 资助金额:
$ 11.59万 - 项目类别:
Mechanistic Studies of NAD+/NADH in Human Heart Failure
NAD/NADH 在人类心力衰竭中的作用机制研究
- 批准号:
10006334 - 财政年份:2019
- 资助金额:
$ 11.59万 - 项目类别:
Mechanistic Studies of NAD+/NADH in Human Heart Failure
NAD/NADH 在人类心力衰竭中的作用机制研究
- 批准号:
10470297 - 财政年份:2019
- 资助金额:
$ 11.59万 - 项目类别:
Mechanistic Studies of NAD+/NADH in Human Heart Failure
NAD/NADH 在人类心力衰竭中的作用机制研究
- 批准号:
10908777 - 财政年份:2019
- 资助金额:
$ 11.59万 - 项目类别:
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
AIM-HIGH 中的斑块炎症和 HDL 功能障碍
- 批准号:
8300144 - 财政年份:2008
- 资助金额:
$ 11.59万 - 项目类别:
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
AIM-HIGH 中的斑块炎症和 HDL 功能障碍
- 批准号:
7615104 - 财政年份:2008
- 资助金额:
$ 11.59万 - 项目类别:
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
AIM-HIGH 中的斑块炎症和 HDL 功能障碍
- 批准号:
8067139 - 财政年份:2008
- 资助金额:
$ 11.59万 - 项目类别:
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
AIM-HIGH 中的斑块炎症和 HDL 功能障碍
- 批准号:
7822854 - 财政年份:2008
- 资助金额:
$ 11.59万 - 项目类别:
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
AIM-HIGH 中的斑块炎症和 HDL 功能障碍
- 批准号:
7462430 - 财政年份:2008
- 资助金额:
$ 11.59万 - 项目类别:
相似海外基金
Determining 4-Dimensional Foot Loading Profiles of Healthy Adults across Activities of Daily Living
确定健康成年人日常生活活动的 4 维足部负荷曲线
- 批准号:
2473795 - 财政年份:2024
- 资助金额:
$ 11.59万 - 项目类别:
Studentship
Developing a trunk function assessment for hemiplegics. -For improving activities of daily living-
开发偏瘫患者的躯干功能评估。
- 批准号:
23K10540 - 财政年份:2023
- 资助金额:
$ 11.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Relation with the activities of daily living and the subjective values among people with social withdrawal
社交退缩者日常生活活动与主观价值观的关系
- 批准号:
23K16596 - 财政年份:2023
- 资助金额:
$ 11.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CRII: RI: Understanding Activities of Daily Living in Indoor Scenarios
CRII:RI:了解室内场景中的日常生活活动
- 批准号:
2245652 - 财政年份:2023
- 资助金额:
$ 11.59万 - 项目类别:
Standard Grant
Association between Nursing Care and Prognosis and Activities of Daily Living in Acute Stroke patients by using Big Data.
利用大数据研究急性脑卒中患者的护理与预后和日常生活活动的关系。
- 批准号:
23K16412 - 财政年份:2023
- 资助金额:
$ 11.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Sources of vulnerability among those using homecare despite having no limitations in Activities of Daily Living. An intersectionality analysis
尽管日常生活活动没有限制,但使用家庭护理的人的脆弱性来源。
- 批准号:
499112 - 财政年份:2023
- 资助金额:
$ 11.59万 - 项目类别:
Operating Grants
Synergizing home health rehabilitation therapy to optimize patients’ activities of daily living
协同家庭健康康复治疗,优化患者的日常生活活动
- 批准号:
10429480 - 财政年份:2022
- 资助金额:
$ 11.59万 - 项目类别:
Effects of a model of nurses-occupational therapists collaborative practice on activities of daily living in elderly patients
护士-职业治疗师合作实践模式对老年患者日常生活活动的影响
- 批准号:
22K17540 - 财政年份:2022
- 资助金额:
$ 11.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Assessing a Novel Virtual Environment that Primes Individuals Living with AD/ADRD to Accomplish Activities of Daily Living.
评估一种新颖的虚拟环境,该环境可以帮助 AD/ADRD 患者完成日常生活活动。
- 批准号:
10668160 - 财政年份:2022
- 资助金额:
$ 11.59万 - 项目类别:
Synergizing home health rehabilitation therapy to optimize patients’ activities of daily living
协同家庭健康康复治疗,优化患者的日常生活活动
- 批准号:
10621820 - 财政年份:2022
- 资助金额:
$ 11.59万 - 项目类别: